Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Guangdong Marubi Biotechnology

SHSE:603983
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
603983
SHSE
CN¥28B
Market Cap
  1. Home
  2. CN
  3. Household
Company description

Guangdong Marubi Biotechnology Co., Ltd. provides eye care product under the Maru brand in China. The last earnings update was 154 days ago. More info.


Add to Portfolio Compare Print
603983 Share Price and Events
7 Day Returns
4.2%
SHSE:603983
2.5%
CN Personal Products
2.3%
CN Market
1 Year Returns
-
SHSE:603983
-17.8%
CN Personal Products
-8.9%
CN Market
603983 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Guangdong Marubi Biotechnology (603983) 4.2% -8.7% 15.3% - - -
CN Personal Products 2.5% -3% -1.9% -17.8% -20.8% -42.5%
CN Market 2.3% -6.7% -6.1% -8.9% -15.5% -24.4%
1 Year Return vs Industry and Market
  • No trading data on 603983.
  • No trading data on 603983.
Price Volatility
Industry
5yr Volatility vs Market

603983 Value

 Is Guangdong Marubi Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Guangdong Marubi Biotechnology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Guangdong Marubi Biotechnology.

SHSE:603983 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SHSE:603983
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.601 (1 + (1- 25%) (0%))
0.733
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.8 * 6.33%)
8.26%

Discounted Cash Flow Calculation for SHSE:603983 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Guangdong Marubi Biotechnology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SHSE:603983 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.26%)
2020 587.99 Est @ 9.58% 543.11
2021 633.06 Est @ 7.66% 540.10
2022 673.10 Est @ 6.33% 530.43
2023 709.37 Est @ 5.39% 516.34
2024 742.93 Est @ 4.73% 499.49
2025 774.67 Est @ 4.27% 481.07
2026 805.27 Est @ 3.95% 461.90
2027 835.27 Est @ 3.73% 442.54
2028 865.07 Est @ 3.57% 423.34
2029 894.98 Est @ 3.46% 404.55
Present value of next 10 years cash flows CN¥4,842.00
SHSE:603983 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥894.98 × (1 + 3.2%) ÷ (8.26% – 3.2%)
CN¥18,238.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥18,238.85 ÷ (1 + 8.26%)10
CN¥8,244.36
SHSE:603983 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥4,842.00 + CN¥8,244.36
CN¥13,086.36
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥13,086.36 / 401.00
CN¥32.63
SHSE:603983 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥32.63
Current discount Discount to share price of CN¥69.19
= -1 x (CN¥69.19 - CN¥32.63) / CN¥32.63
-112%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Guangdong Marubi Biotechnology is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Guangdong Marubi Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Guangdong Marubi Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SHSE:603983 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥1.45
SHSE:603983 Share Price ** SHSE (2020-03-31) in CNY CN¥69.19
China Personal Products Industry PE Ratio Median Figure of 13 Publicly-Listed Personal Products Companies 31.19x
China Market PE Ratio Median Figure of 3,186 Publicly-Listed Companies 31.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Guangdong Marubi Biotechnology.

SHSE:603983 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SHSE:603983 Share Price ÷ EPS (both in CNY)

= 69.19 ÷ 1.45

47.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guangdong Marubi Biotechnology is overvalued based on earnings compared to the CN Personal Products industry average.
  • Guangdong Marubi Biotechnology is overvalued based on earnings compared to the China market.
Price based on expected Growth
Does Guangdong Marubi Biotechnology's expected growth come at a high price?
Raw Data
SHSE:603983 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 47.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
19.8%per year
China Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.3x
China Market PEG Ratio Median Figure of 1,276 Publicly-Listed Companies 1.23x

*Line of best fit is calculated by linear regression .

SHSE:603983 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 47.64x ÷ 19.8%

2.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guangdong Marubi Biotechnology is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Guangdong Marubi Biotechnology's assets?
Raw Data
SHSE:603983 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥6.27
SHSE:603983 Share Price * SHSE (2020-03-31) in CNY CN¥69.19
China Personal Products Industry PB Ratio Median Figure of 15 Publicly-Listed Personal Products Companies 2.65x
China Market PB Ratio Median Figure of 3,687 Publicly-Listed Companies 2.24x
SHSE:603983 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SHSE:603983 Share Price ÷ Book Value per Share (both in CNY)

= 69.19 ÷ 6.27

11.04x

* Primary Listing of Guangdong Marubi Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guangdong Marubi Biotechnology is overvalued based on assets compared to the CN Personal Products industry average.
X
Value checks
We assess Guangdong Marubi Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Guangdong Marubi Biotechnology has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

603983 Future Performance

 How is Guangdong Marubi Biotechnology expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Guangdong Marubi Biotechnology expected to grow at an attractive rate?
  • Guangdong Marubi Biotechnology's earnings growth is expected to exceed the low risk savings rate of 3.2%.
Growth vs Market Checks
  • Guangdong Marubi Biotechnology's earnings growth is positive but not above the China market average.
  • Guangdong Marubi Biotechnology's revenue growth is expected to exceed the China market average.
Annual Growth Rates Comparison
Raw Data
SHSE:603983 Future Growth Rates Data Sources
Data Point Source Value (per year)
SHSE:603983 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 19.8%
SHSE:603983 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 19.8%
China Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 27.9%
China Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 16.9%
China Market Earnings Growth Rate Market Cap Weighted Average 21%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SHSE:603983 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SHSE:603983 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,695 874 786 6
2020-12-31 2,242 692 654 6
2020-03-31
2019-12-31 1,851 589 530 6
SHSE:603983 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 1,732 544 539
2019-06-30 1,662 562 477
2019-03-31 1,606 481 440
2018-12-31 1,576 517 415
2017-12-31 1,352 356 312
2016-12-31 1,208 213 232

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Guangdong Marubi Biotechnology's earnings are expected to grow by 19.8% yearly, however this is not considered high growth (20% yearly).
  • Guangdong Marubi Biotechnology's revenue is expected to grow by 19.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SHSE:603983 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Guangdong Marubi Biotechnology Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:603983 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 1.96 2.38 1.70 6.00
2020-12-31 1.61 1.85 1.47 7.00
2020-03-31
2019-12-31 1.31 1.45 1.24 7.00
SHSE:603983 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 1.45
2019-06-30 1.32
2019-03-31 1.21
2018-12-31 1.15
2017-12-31 0.87
2016-12-31 0.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Guangdong Marubi Biotechnology is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Guangdong Marubi Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Guangdong Marubi Biotechnology has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

603983 Past Performance

  How has Guangdong Marubi Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Guangdong Marubi Biotechnology's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if Guangdong Marubi Biotechnology's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Guangdong Marubi Biotechnology's 1-year earnings growth to the 5-year average due to insufficient past data.
  • Guangdong Marubi Biotechnology's earnings growth has exceeded the CN Personal Products industry average in the past year (38.4% vs -0.4%).
Earnings and Revenue History
Guangdong Marubi Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Guangdong Marubi Biotechnology Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:603983 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1,731.70 538.53 613.37 36.78
2019-06-30 1,662.09 476.78 626.96 34.93
2019-03-31 1,605.51 439.53 605.30 34.27
2018-12-31 1,575.76 415.28 606.41 33.82
2017-12-31 1,352.32 311.92 535.84 28.30
2016-12-31 1,208.13 232.19 530.46 24.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Guangdong Marubi Biotechnology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Guangdong Marubi Biotechnology used its assets more efficiently than the CN Personal Products industry average last year based on Return on Assets.
  • Unable to establish if Guangdong Marubi Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Guangdong Marubi Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Guangdong Marubi Biotechnology has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

603983 Health

 How is Guangdong Marubi Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Guangdong Marubi Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Guangdong Marubi Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Guangdong Marubi Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Guangdong Marubi Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Guangdong Marubi Biotechnology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Guangdong Marubi Biotechnology Company Filings, last reported 6 months ago.

SHSE:603983 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 2,513.97 0.00 2,711.19
2019-06-30 1,636.54 0.00 1,838.01
2019-03-31 1,501.81 0.00 1,100.13
2018-12-31 1,381.86 0.00 1,633.45
2017-12-31 959.96 0.00 1,103.00
2016-12-31 828.09 20.60 941.47
  • Guangdong Marubi Biotechnology has no debt.
  • Guangdong Marubi Biotechnology currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Guangdong Marubi Biotechnology has no debt, it does not need to be covered by operating cash flow.
  • Guangdong Marubi Biotechnology has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Guangdong Marubi Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Guangdong Marubi Biotechnology has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

603983 Dividends

 What is Guangdong Marubi Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Guangdong Marubi Biotechnology dividends. Estimated to be 1.18% next year.
If you bought CN¥2,000 of Guangdong Marubi Biotechnology shares you are expected to receive CN¥0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Guangdong Marubi Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Guangdong Marubi Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SHSE:603983 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
China Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
China Market Average Dividend Yield Market Cap Weighted Average of 2581 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SHSE:603983 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.88 1.00
2020-12-31 0.75 1.00
2020-03-31
2019-12-31 0.62 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Guangdong Marubi Biotechnology has not reported any payouts.
  • Unable to verify if Guangdong Marubi Biotechnology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Guangdong Marubi Biotechnology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Guangdong Marubi Biotechnology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Guangdong Marubi Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Guangdong Marubi Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Guangdong Marubi Biotechnology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

603983 Management

 What is the CEO of Guangdong Marubi Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Huaiqing Sun
CEO Bio

Sun, Huaiqing serves as Chief Executive Officer at Guangdong Marubi Biotechnology Co., Ltd.

CEO Compensation
  • Insufficient data for Huaiqing to compare compensation growth.
  • Insufficient data for Huaiqing to establish whether their remuneration is reasonable compared to companies of similar size in China.
Management Team

Huaiqing Sun

TITLE
Chief Executive Officer
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Guangdong Marubi Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Guangdong Marubi Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

603983 News

Simply Wall St News

603983 Company Info

Description

Guangdong Marubi Biotechnology Co., Ltd. provides eye care product under the Maru brand in China. It offers eye cream and facial series products through e-commerce platform. The company is based in Guangzhou, China.

Details
Name: Guangdong Marubi Biotechnology Co., Ltd.
603983
Exchange: SHSE
Founded:
CN¥27,745,190,000
401,000,000
Website: http://www.marubi.cn
Address: Guangdong Marubi Biotechnology Co., Ltd.
No. 11, Yucun Road,
Zhujiang New Town,
Guangzhou,
Guangdong Province, 510000,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SHSE 603983 Domestic Shares Shanghai Stock Exchange CN CNY 25. Jul 2019
XSSC 603983 Domestic Shares Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect CN CNY 25. Jul 2019
Number of employees
Current staff
Staff numbers
889
Guangdong Marubi Biotechnology employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:01
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2019/10/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.